Homoharringtonine clinical trials
Also written Homoharringtonine, omacetaxine mepesuccinate and CGX-635.
How each study uses Homoharringtonine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Homoharringtonine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 26 Oct 2012 · SYNRIBO · NDA 203585 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
39 studies that test it; most in 2024 (6)
| Year | Studies |
|---|---|
| 1994 | 1 |
| 1998 | 1 |
| 1999 | 2 |
| 2000 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2011 | 1 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 6 |
| 2025 | 4 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 34
Institute of Hematology & Blood Diseases Hospital, China (5) · Teva Branded Pharmaceutical Products R&D, Inc. (4) · M.D. Anderson Cancer Center (4) · National Cancer Institute (NCI) (4) · First Affiliated Hospital of Zhejiang University (2) · The University of Hong Kong (2) · ChemGenex Pharmaceuticals (2) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (2)
Often tested with
Tested in the same studies.
Cytarabine (9) · Venetoclax (8) · Azacitidine (7) · Decitabine (4) · Idarubicin (3) · Mitoxantrone (3) · Granulocyte Colony-Stimulating Factor (3) · Antiandrogen Therapy (2)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test Homoharringtonine.
- Aug 2027Intermediate-dose HAD Regimen for CEBPA Double-mutated AMLNot applicable · Institute of Hematology & Blood Diseases Hospital, China
- Sep 2027Homoharringtonine Plus Androgen Deprivation Therapy in the Neoadjuvant Treatment of Prostate Cancer: A Single-Arm Clinical StudyPhase 2 · baotai Liang
Studies
Open first, then newest update. How each study uses Homoharringtonine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 40
- Intermediate-dose HAD Regimen for CEBPA Double-mutated AMLRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT06529250Written as HADHow we know
- MRD-positive AML Clinical StudyRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT07131059Written as HomoharringtonineHow we know
- Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid LeukemiaRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT06265545Written as HomoharringtonineHow we know
- VAH vs VA in Newly Diagnosed Elderly AMLNot yet recruitingPhase 3Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineNCT07469046Written as HomoharringtonineHow we know
- Safety and Efficacy of Docetaxel, Darolutamide, and Homoharringtonine Combined With Androgen Deprivation Therapy in Neoadjuvant Treatment of High-Risk Prostate Cancer: A Multicenter Prospective, Single-Arm Clinical StudyNot yet recruitingEarly Phase 1Zhongda HospitalNCT07516704Written as Docetaxel+ Darolutamide + Homoharringtonine+ Androgen Deprivation TherapyHow we know
- Efficacy and Safety of Lisafotoclax Plus Decitabine and Homoharringtonine in Venetoclax/Azacitidine Pretreated AML PatientsNot yet recruitingPhase 2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT07505160Written as HomoharringtonineHow we know
- Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML.RecruitingPhase 2Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineNCT06483906Written as Venetoclax, Azacitidine and HomoharringtonineHow we know
- Homoharringtonine Plus Androgen Deprivation Therapy in the Neoadjuvant Treatment of Prostate Cancer: A Single-Arm Clinical StudyRecruitingPhase 2baotai LiangNCT07163910Written as homoharringtonineHow we know
- Clinical Study on Neoadjuvant Therapy of Homoharringtonine Combined With Androgen Deprivation for Prostate CancerRecruitingPhase 2baotai LiangNCT06834321Written as Homoharringtonine combined with androgen deprivation therapyHow we know
- Newly-diagnosed Pediatric T-cell ALL ProtocolRecruitingPhase 2/3Institute of Hematology & Blood Diseases Hospital, ChinaNCT06855810Written as homoharringtonineHow we know
- Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALLRecruitingPhase 3First Affiliated Hospital of Zhejiang UniversityNCT06361329Written as HomoharringtonineHow we know
- Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AMLRecruitingPhase 2Children's Hospital of Soochow UniversityNCT06221683Written as HomoharringtonineHow we know
- Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AMLRecruitingPhase 2/3The First Affiliated Hospital of Soochow UniversityNCT05805098Written as HomoharringtonineHow we know
- Omacetaxine + Azacitidine in Untreated Patients With High Grade MDSActive, not recruitingPhase 1/2University of Colorado, DenverNCT03564873Written as OmacetaxineHow we know
- HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AMLActive, not recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT06744556Written as HomoharringtonineHow we know
- Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML)CompletedPhase 1University of Illinois at ChicagoNCT04926285Written as OmacetaxineHow we know
- Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid LeukemiaCompletedPhase 2First Affiliated Hospital of Zhejiang UniversityNCT05906914Written as cladribine + homoharringtonine + cytarabineHow we know
- VAH Versus VA for Salvage Therapy of R/R-AMLStatus unknownPhase 3Nanfang Hospital, Southern Medical UniversityNCT05457361Written as VEN combined with azacitidine plus homoharringtonineHow we know
- Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CMLCompletedPhase 2Teva Branded Pharmaceutical Products R&D, Inc.NCT00462943Written as Omacetaxine mepesuccinateHow we know
- Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene MutationCompletedPhase 2Teva Branded Pharmaceutical Products R&D, Inc.NCT00375219Written as Omacetaxine mepesuccinateHow we know
See all 40 studies that test Homoharringtonine →
Given beside what is tested · 11 — Homoharringtonine is usual care or a partner of the new treatment
- Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy FailureEnrolling by invitationPhase 2Guangdong Second Provincial General HospitalNCT07813390Written as homoharringtonineHow we know
- Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive ChemotherapyEnrolling by invitationPhase 2/3First Affiliated Hospital of Zhejiang UniversityNCT07651163Written as Lisaftoclax+homoharringtonine+cytarabine+aclarubicinHow we know
- Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive ChemotherapyEnrolling by invitationPhase 2/3First Affiliated Hospital of Zhejiang UniversityNCT07651176Written as Lisaftoclax+homoharringtonine+cytarabine+aclarubicinHow we know
- Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AMLRecruitingPhase 1/2Ascentage Pharma Group Inc.NCT04501120Written as standard-dose HHTHow we know
- Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell LymphomaNot yet recruitingPhase 1/2First Affiliated Hospital of Zhejiang UniversityNCT07159906Written as HomoharringtonineHow we know
- VHAG in Treating R/R T-ALL/LBLRecruitingPhase 2First Affiliated Hospital of Zhejiang UniversityNCT06742463Written as homoharringtonineHow we know
- Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid LeukemiaRecruitingPhase 3Shanxi Bethune HospitalNCT05726110Written as HomoharringtonineHow we know
- Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) PatientsNot yet recruitingNot applicableThe First Affiliated Hospital of Soochow UniversityNCT05805072Written as HomoharringtonineHow we know
- Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1TerminatedPhase 1/2M.D. Anderson Cancer CenterNCT04874194Written as Omacetaxine MepesuccinateHow we know
- Study of Azacitidine Combined With Homoharringtonie Based Regimens in AMLStatus unknownPhase 2Ge ZhengNCT04248595Written as HomoharringtonineHow we know
- AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML PatientsTerminatedPhase 1/2University of Illinois at ChicagoNCT02440568Written as Omacetaxine mepesuccinateHow we know
As the comparator · 1 — what is tested is compared with Homoharringtonine
Codes
What other systems call Homoharringtonine · ClinicalTrials.gg INT006810
- MeSH (NLM) D000077863HomoharringtonineConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 6FG8041S5BOMACETAXINE MEPESUCCINATEConfirmed FDA, NLM, Wikidata
- RxNorm 27100Confirmed FDA, Wikidata
- Wikidata Q7089373(-)-homoharringtonineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1127Omacetaxine MepesuccinateConfirmed FDA, Wikidata
- DrugBank DB04865One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077863 | Homoharringtonine | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 6FG8041S5B | OMACETAXINE MEPESUCCINATE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 27100 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7089373 | (-)-homoharringtonine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1127 | Omacetaxine Mepesuccinate | Confirmed FDA, Wikidata |
| DrugBank | DB04865 | — | One source Wikidata |
Also registered as omacetaxine (UNII 84MI6OYN4Z · RxNorm 1546446).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.